This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
UBE2D2 / Ubiquitin-conjugating enzyme E2 D2 · Western blot design guide
Design a Western Blot for UBE2D2
Source-linked UBE2D2 Western blot protocol options, expected-band and isoform facts, troubleshooting for weak or shifted signal, and recommended anti-UBE2D2 WB antibodies. Everything you need to plan the experiment before you commit precious samples.
Evidence assembled September 2026 · For research use; verify linked source records and product datasheet before use
UBE2D2 Western Blot Experimental Design Guide
Expected bands, source-linked protocol options, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | ~16.7 kDa | |
| Gel | 15% (standard starting point) | |
| Positive control | Adipose tissue (IHC candidate; verify WB) +4 more | |
| Negative control | Adrenal gland (IHC candidate; verify WB) |
Important caveats
Reasons your observed band may differ from the expected size.
| PTM | — | |
| Caveat | — | |
| Gene-set association | MSigDB C7 membership | |
| Isoform | 2 isoform(s) |
Section 1
Source-Linked UBE2D2 Western Blot Protocol Options
The A03971 protocol combines labelled catalog values with standard starting conditions. Published comparisons retain their own sample, reagent and detection scope.
| Sample / lysate | Hela, Raw264.7, H9C2 (catalog A03971) |
| Gel % | 15% (standard starting point) |
| Load | 20–30 µg total protein per lane; optimize for abundance (standard starting point) |
| Transfer | Short semi-dry transfer; verify retention (standard starting point) |
| Membrane | 0.2 µm PVDF (standard starting point) |
| Blocking | 5% milk or 5% BSA in TBST (standard starting point) |
| Primary antibody | A03971; use the WB datasheet starting dilution (standard starting point) |
| Primary incubation | Overnight at 4 °C (standard starting point) |
| Secondary antibody | Species-matched HRP conjugate at validated dilution (standard starting point) |
| Secondary incubation | 1 h at room temperature (standard starting point) |
| Wash | 3 × 5 min in TBST (standard starting point) |
| Detection | ECL; bracket exposures to avoid saturation (standard starting point) |
Section 2
What Is the Expected UBE2D2 Western Blot Band Size?
UBE2D2 is predicted at 16.7 kDa; its two isoforms could affect migration, but no empirical band or distinct isoform pattern is established.
| Single band near 16.7 kDa | Consistent with the predicted UBE2D2 mass; identity needs confirmation. |
| One sharp band despite two annotated isoforms | Isoforms 1 and 2 are not necessarily resolved on this blot. |
| Doublet near the predicted size | Could reflect isoforms 1 and 2 if both bands are confirmed as UBE2D2. |
| Several bands at different masses | Could include splice isoforms, but their migration is not established. |
💡Expected UBE2D2 appearanceUBE2D2 has a predicted mass of 16.7 kDa and two annotated isoforms, but no empirical band size or isoform migration is supplied; confirm candidate bands with ordinary identity controls.
| Predicted mass of 16.7 kDa | Provides a reference for a candidate band, not a measured migration. |
| Reference sequence of 147 amino acids | Underlies the supplied 16.7 kDa prediction. |
| Splice isoform 1 | May migrate differently from isoform 2; its mass is not supplied. |
| Splice isoform 2 | May migrate differently from isoform 1; its mass is not supplied. |
| Situation | Likely cause | Next action |
|---|---|---|
| Band higher than expected | An isoform or unrelated signal is possible; no higher migration is established. | Compare with a UBE2D2 knockdown control. |
| Band lower than expected | An isoform or unrelated signal is possible; no lower migration is established. | Check whether the band decreases after UBE2D2 knockdown. |
| Multiple bands | Two splice isoforms are annotated, but distinct bands are not established. | Use UBE2D2 knockdown to identify responsive bands. |
| Weak or no signal | Target abundance or antibody detection may be insufficient. | Check lysate loading and use a positive lysate control. |
| Fragments below expected size | Sample degradation is possible; no cleavage product is annotated. | Check sample handling and compare fresh lysate with a UBE2D2 knockdown control. |
Experiment evidence
Western blot images showing UBE2D2 band
A03971 · UBE2D2
A03971-1 · UBE2D2
A03971-1 · UBE2D2
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for UBE2D2 Western blot
🧪HPA-IHC candidate guidance (verify in WB): For positive controls for UBE2D2 in Western blot, you can use adipose tissue lysate.
Positive control: Adipose tissue (IHC candidate; verify WB)
Negative control: Adrenal gland (IHC candidate; verify WB)
Loading controls: Run GAPDH, β-actin, and a total-protein stain such as Ponceau alongside the samples.
⚠️Feasibility: HPA reports medium signal in adipose tissue, so the positive band may be modest.
HPA tissue expression evidence for UBE2D2
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Higher expression tissues · candidate positive controls from IHC
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | adipocytes | Medium | Protein (IHC) | HPA → |
| Bone marrow | hematopoietic cells | Medium | Protein (IHC) | HPA → |
| Breast | glandular cells | Medium | Protein (IHC) | HPA → |
| Colon | glandular cells | Medium | Protein (IHC) | HPA → |
| Fallopian tube | glandular cells | Medium | Protein (IHC) | HPA → |
Lower expression tissues · IHC evidence, not confirmed WB-negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adrenal gland | glandular cells | Not detected | Protein (IHC) | HPA → |
| Bronchus | respiratory epithelial cells | Not detected | Protein (IHC) | HPA → |
| Duodenum | glandular cells | Not detected | Protein (IHC) | HPA → |
| Esophagus | squamous epithelial cells | Not detected | Protein (IHC) | HPA → |
| Heart muscle | cardiomyocytes | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced UBE2D2 Western Blot Tips
Deeper troubleshooting and optimisation questions for UBE2D2, answered from its protein features.
How should UBE2D2 band migration be interpreted?
Band shift · Use the separately labelled calculated mass and catalog-observed evidence above. A sequence annotation does not establish an observed migration shift. Verify target identity with orthogonal controls.
Could UBE2D2 isoforms produce different bands?
Isoforms · UniProt lists two isoforms. Isoform 2 lacks residues 1–29 of the 147-residue canonical sequence, so it has a shorter sequence. Whether the isoforms resolve as separate bands is not established by these features.
Choose an epitope outside canonical residues 1–29, which are missing from isoform 2. An antibody against that N-terminal segment would not be expected to detect isoform 2.
Use an antibody whose epitope is retained in both isoforms if the goal is to measure both. If two bands are resolved, quantify them separately or define their combined signal consistently; the supplied features do not establish which bands will appear.
Choose an epitope outside canonical residues 1–29, which are missing from isoform 2. An antibody against that N-terminal segment would not be expected to detect isoform 2.
Use an antibody whose epitope is retained in both isoforms if the goal is to measure both. If two bands are resolved, quantify them separately or define their combined signal consistently; the supplied features do not establish which bands will appear.
Do the listed modifications explain a shifted UBE2D2 band?
PTM · No modified residues or glycosylation sites are listed. These features do not establish a modification-related shift, and no observed band position is available to compare with the predicted 16.7 kDa mass.
Does this guide establish induction of UBE2D2?
Induction · No general induction response is established by this guide. A pathway or gene-set association is not evidence of induction in a particular specimen. Verify the relevant treatment and control in a target-specific experiment.
How should transfer be checked for UBE2D2?
Transfer · Standard workflow guidance: verify transfer efficiency for the intended target size before interpreting a weak signal. Use total-protein assessment and optimize transfer for the membrane, gel and apparatus; the labelled catalog values take precedence.
How should blocking be optimized?
Blocking · Standard workflow guidance: follow the A03971 datasheet where specified. Otherwise compare 5% milk or 5% BSA in TBST; for a phospho-specific assay start with BSA. Optimize background and specific signal with matched controls.
How should UBE2D2 be quantified?
Quantitation · Standard workflow guidance: quantify only a validated target band within the linear exposure range. Use consistent sample preparation and loading, retain biological replicates, and avoid interpreting saturation or loading differences as regulation.
What molecular weight should I expect for UBE2D2?
Interpretation · Canonical UBE2D2 has a predicted mass of 16.7 kDa. No observed Western blot band position is supplied, so use 16.7 kDa as a reference rather than an established apparent mass.
Consider isoform 2 because it lacks canonical residues 1–29. Check whether the antibody epitope is retained in isoform 2; the sequence difference alone does not confirm the identity or apparent position of a lower band.
UBE2D2 is listed as interacting with the SCF complex, CNOT4, CBLC, PJA1, PJA2, and PDZRN3. Those interactions alone do not establish that a higher Western blot band contains UBE2D2 or any particular partner.
Consider isoform 2 because it lacks canonical residues 1–29. Check whether the antibody epitope is retained in isoform 2; the sequence difference alone does not confirm the identity or apparent position of a lower band.
UBE2D2 is listed as interacting with the SCF complex, CNOT4, CBLC, PJA1, PJA2, and PDZRN3. Those interactions alone do not establish that a higher Western blot band contains UBE2D2 or any particular partner.
Boster reagents
UBE2D2 Western Blot Antibodies
Catalog antibodies with Western blot application and product-specific WB images. Evaluate suitability with the reported sample, controls and experimental conditions.
Real WB data
Anti-UBE2D2 Antibody
Cat # A03971
Real WB data
Anti-UBE2D2/Ubch5B Antibody
Cat # A03971-1
Both listed anti-UBE2D2 antibodies report Human, Mouse, and Rat reactivity and have WB images. A03971’s caption names HeLa, RAW264.7, and H9C2 lysates; A03971-1’s caption says only ‘various cells.’ These examples do not establish validation across all reported species.
Which to pick: Choose A03971 if you want a WB image with named lysates and a reported 1:500 primary dilution. A03971-1 also has a WB image, with a 1:2000 primary dilution, but its caption does not identify the cells. Both report the same species reactivity.
Source: BosterBio UBE2D2 gene-info card — filtered to Western-blot-capable antibodies; each card shows that product's actual WB validation figure.
References
- UniProt Consortium. UniProt entry P62837.
- Human Protein Atlas. UBE2D2 tissue expression.
- PMC13098273 — target-verified WB comparison
- PMC11551608 — target-verified WB comparison
- PMC10234107 — target-verified WB comparison